BIEL #1 on the Breakout Board all day Sunday (SpaceX was #5), with nearly double - 130,000 more - reads than SpaceX.
Electrome traction metrics from the company's pitch deck - designed to prove commercial viability, defensibility, and market validation to potential investors or partners:
Defensible Technology: They have exclusive rights to a unique, FDA-cleared (510(k)) bioelectric medical device that can be sold both over-the-counter (OTC) and via prescription (Rx) for pain, swelling, and post-surgery healing.
High Profitability & Validation: They are already generating revenue by selling to the Veterans Affairs (VA) hospital system at an incredibly high 87% gross margin.
Digital Infrastructure: They have a functioning telehealth or digital health platform already live (painkiller.care).
Government Backing / Funding: They qualify for insurance reimbursement under the Center for Medicare & Medicaid Services (CMS) "No Pain Act," which incentivizes non-opioid pain management.
Scalable Distribution: They have Letters of Intent (LOIs) from 3,700 independent pharmacies, proving strong B2B market demand.
Intellectual Property (IP): They are protecting their tech with a mix of 12 total patents (licensed, provisional, and pending utility patents).
BIEL BENEFITS
The NOPAIN Act (Non-Opioids Prevent Addiction in the Nation Act) is a game-changing piece of U.S. federal legislation designed to combat the opioid crisis. To truly understand its impact on BIEL, you have to look at how medical billing traditionally worked versus how it works now.
The Old "Bundling" Problem (The Barrier)
Historically, when a patient had surgery at a Hospital Outpatient Department (HOPD) or an Ambulatory Surgical Center (ASC), Medicare paid the facility a single, flat "bundled" fee for the entire procedure.
This bundle covered the operating room, the gowns, the anesthesia, and any postoperative pain management.
Because generic opioid pills are incredibly cheap (often costing just pennies), facilities defaulted to prescribing opioids to protect their profit margins.
If a hospital wanted to use an innovative, non-opioid medical device that cost $200, the hospital had to eat that cost out of their flat fee. This created a massive financial disincentive for doctors to use safer tech.
The NOPAIN Act Solution (The Catalyst)
The NOPAIN Act mandates that the Centers for Medicare & Medicaid Services (CMS) provide separate, additional reimbursement for qualifying non-opioid pain management treatments used in outpatient and ASC settings.
The Impact: Instead of absorbing the cost, hospitals and surgical centers can bill Medicare separately for BIEL's device. The financial barrier is completely erased, making it easy for healthcare administrators and surgeons to choose non-addictive pain relief over opioids.
Insurance Coverage & Reimbursement
For any medical device company, insurance coverage is the ultimate "make or break" factor. The highlights point out two distinct pillars of BIEL's reimbursement strategy:
Government/Medicare Coverage (Top-Down Validation)
Because the federal government (CMS) is actively backing non-opioid treatments under the NOPAIN Act, BIEL / Electrome qualifies for a specific billing code (like a HCPCS code).
When a device is cleared for Medicare reimbursement, commercial insurance providers (Blue Cross, Aetna, Cigna, etc.) usually follow suit. Commercial insurers look at CMS decisions as the gold standard for clinical and financial utility.
B2B and Telehealth Infrastructure (Bottom-Up Access)
BIEL / Electrome isn't relying solely on hospital settings; they have built a dual-track ecosystem to secure insurance dollars:
The Telehealth Platform (painkiller.care): This allows them to bypass traditional doctor visits. A patient experiencing pain can log on, consult with a remote doctor via telehealth, and get a prescription for the device online.
Independent Pharmacies (3,700 LOIs): Once that telehealth doctor writes the prescription, it is sent to a pharmacy. Because the device has prescription (Rx) status and a valid insurance billing pathway, the pharmacy can run the patient's insurance just like a regular drug, making the out-of-pocket cost minimal for the consumer.
Summary
The NOPAIN Act and robust insurance pathways transform BIEL's device from an "expensive alternative" into an "accessible, fully-reimbursed standard of care." For investors, this represents a wide-open highway to rapid commercial scaling.
Electrome traction metrics from the company's pitch deck - designed to prove commercial viability, defensibility, and market validation to potential investors or partners:
Defensible Technology: They have exclusive rights to a unique, FDA-cleared (510(k)) bioelectric medical device that can be sold both over-the-counter (OTC) and via prescription (Rx) for pain, swelling, and post-surgery healing.
High Profitability & Validation: They are already generating revenue by selling to the Veterans Affairs (VA) hospital system at an incredibly high 87% gross margin.
Digital Infrastructure: They have a functioning telehealth or digital health platform already live (painkiller.care).
Government Backing / Funding: They qualify for insurance reimbursement under the Center for Medicare & Medicaid Services (CMS) "No Pain Act," which incentivizes non-opioid pain management.
Scalable Distribution: They have Letters of Intent (LOIs) from 3,700 independent pharmacies, proving strong B2B market demand.
Intellectual Property (IP): They are protecting their tech with a mix of 12 total patents (licensed, provisional, and pending utility patents).
BIEL BENEFITS
The NOPAIN Act (Non-Opioids Prevent Addiction in the Nation Act) is a game-changing piece of U.S. federal legislation designed to combat the opioid crisis. To truly understand its impact on BIEL, you have to look at how medical billing traditionally worked versus how it works now.
The Old "Bundling" Problem (The Barrier)
Historically, when a patient had surgery at a Hospital Outpatient Department (HOPD) or an Ambulatory Surgical Center (ASC), Medicare paid the facility a single, flat "bundled" fee for the entire procedure.
This bundle covered the operating room, the gowns, the anesthesia, and any postoperative pain management.
Because generic opioid pills are incredibly cheap (often costing just pennies), facilities defaulted to prescribing opioids to protect their profit margins.
If a hospital wanted to use an innovative, non-opioid medical device that cost $200, the hospital had to eat that cost out of their flat fee. This created a massive financial disincentive for doctors to use safer tech.
The NOPAIN Act Solution (The Catalyst)
The NOPAIN Act mandates that the Centers for Medicare & Medicaid Services (CMS) provide separate, additional reimbursement for qualifying non-opioid pain management treatments used in outpatient and ASC settings.
The Impact: Instead of absorbing the cost, hospitals and surgical centers can bill Medicare separately for BIEL's device. The financial barrier is completely erased, making it easy for healthcare administrators and surgeons to choose non-addictive pain relief over opioids.
Insurance Coverage & Reimbursement
For any medical device company, insurance coverage is the ultimate "make or break" factor. The highlights point out two distinct pillars of BIEL's reimbursement strategy:
Government/Medicare Coverage (Top-Down Validation)
Because the federal government (CMS) is actively backing non-opioid treatments under the NOPAIN Act, BIEL / Electrome qualifies for a specific billing code (like a HCPCS code).
When a device is cleared for Medicare reimbursement, commercial insurance providers (Blue Cross, Aetna, Cigna, etc.) usually follow suit. Commercial insurers look at CMS decisions as the gold standard for clinical and financial utility.
B2B and Telehealth Infrastructure (Bottom-Up Access)
BIEL / Electrome isn't relying solely on hospital settings; they have built a dual-track ecosystem to secure insurance dollars:
The Telehealth Platform (painkiller.care): This allows them to bypass traditional doctor visits. A patient experiencing pain can log on, consult with a remote doctor via telehealth, and get a prescription for the device online.
Independent Pharmacies (3,700 LOIs): Once that telehealth doctor writes the prescription, it is sent to a pharmacy. Because the device has prescription (Rx) status and a valid insurance billing pathway, the pharmacy can run the patient's insurance just like a regular drug, making the out-of-pocket cost minimal for the consumer.
Summary
The NOPAIN Act and robust insurance pathways transform BIEL's device from an "expensive alternative" into an "accessible, fully-reimbursed standard of care." For investors, this represents a wide-open highway to rapid commercial scaling.
1
